Amyloid-Journal of Protein Folding Disorders

Papers
(The median citation count of Amyloid-Journal of Protein Folding Disorders is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Changes in the amyloid editorial board members and in editor positions279
A case of asymmetric insulin-derived localised amyloid deposition associated with long-acting insulin analog administration268
A second case of liraglutide-type localised amyloidosis107
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies81
Impact of autonomic dysfunction in light chain amyloidosis patient with nephrotic syndrome and cardiac involvement74
Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey34
Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis − correlation between neurofilament light chain and nerve conduction study32
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis25
Commentary to revisiting the genetic epidemiology of ATTRv in Spain: the Balearic Islands as a high-prevalence founder focus24
Reduction of cardiac AL amyloid deposition after complete response visualised by PiB-PET imaging22
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases22
A novel transthyretin variant p.Val114Glu (Val94Glu) in an Italian patient with mixed phenotype hereditary transthyretin amyloidosis21
Early cardiovascular autonomic failure in ATTRv predicts poor prognosis and may respond to disease-modifying therapy20
Genetic landscape of hereditary transthyretin amyloidosis in Spain: a multicentric retrospective study18
Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 light chains18
Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy18
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange18
Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition16
Human lysozyme inhibits the fibrillation of serum amyloid a protein from systemic AA amyloidosis15
Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survival14
Clinical profile and outcome of AA amyloidosis associated kidney disease in India13
Revisiting the genetic epidemiology of ATTRv in Spain: the Balearic Islands as a high-prevalence founder focus13
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay13
Alterations in multi-layer strain in AL amyloidosis13
Identification of epidermal growth factor-containing fibulin-like extracellular matrix protein 1-derived amyloid deposition in a rhesus macaque12
Selective recognition of human small transthyretin aggregates by a novel monoclonal antibody11
Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis11
Clinical and molecular insights into A97S variants in hereditary transthyretin amyloid polyneuropathy in South China11
Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study11
Prevalence and prognostic role of nonsustained ventricular tachycardia in cardiac amyloidosis11
A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)11
Left atrioventricular coupling index assessed with three-dimensional echocardiography: a prognostic marker of short-term outcomes in light-chain cardiac amyloidosis11
Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice11
Refining prognostication in systemic AL amyloidosis: limited value of dFLC10
Mapping cellular response to destabilized transthyretin reveals cell- and amyloidogenic protein-specific signatures10
Involvement of bile acid in diarrhoea and therapeutic effect of colestimide in hereditary ATTR amyloidosis10
Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee10
Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage10
A rare occurrence and near miss! Should a TTR gene test be routinely performed for suspected ATTR-cardiomyopathy?10
Brain MRI in patients with V30M hereditary transthyretin amyloidosis10
Possible transmission of leukocyte chemotactic factor 2 amyloidosis after interpopulational liver transplantation9
AA amyloidosis as an adverse event of immune checkpoint inhibitor therapy: evidence from the FDA adverse event reporting system and a systematic review9
Correction9
Monitoring of cardiac transthyretin amyloid load by [99mTc]DPD scintigraphy: is it the end of the semi-quantitative evaluation?9
Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis9
Change of guard at Amyloid – a tribute to outgoing Editor in Chief, Professor Per Westermark9
Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution9
Incidence and predictors of sudden death in patients with cardiac amyloidosis8
Complete remission after patisiran treatment in a patient with nephrotic syndrome secondary to hereditary transthyretin amyloidosis (ATTR)8
Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study8
Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant8
Prognostic impact of cardiac resynchronization therapy in wild-type transthyretin amyloid cardiomyopathy8
Cold pressor test and paradoxical blood pressure reduction in light chain amyloidosis8
Enhanced analytic methodology enables postmortem diagnosis of hereditary AApoAI amyloidosis7
Altered connectivity of central autonomic network: effects of dysautonomia in hereditary transthyretin amyloidosis with polyneuropathy7
Subtyping of cardiac amyloidosis by mass spectrometry-based proteomics of endomyocardial biopsies7
A family with extremely early onset ATTRv amyloidosis and an F44S mutation in China7
Epidemiology of hereditary transthyretin amyloidosis in the northernmost region of Sweden: a retrospective cohort study7
Reduction in 99m Tc-DPD myocardial uptake with therapy of ATTR cardiomyopathy6
Right ventricular coupling predicts cardiopulmonary fitness in cardiac transthyretin amyloidosis6
Limited diagnostic utility of systematic Congo red staining in bone marrow biopsies6
Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis6
Neuropathy progression in hereditary transthyretin amyloidosis (ATTRv) patients after liver transplantation6
Single-slide detection and typing of AL renal amyloidosis: combining mass spectrometry imaging and digital pathology6
Detection of ATTR aggregates in the plasma of polyneuropathic patients with ATTR-V30M amyloidosis6
Heterogeneity in families with ATTRV30M amyloidosis: a historical and longitudinal Portuguese case study impact for genetic counselling6
Amyloid myopathy in the internal oblique muscle of patients with wild-type transthyretin cardiac amyloidosis5
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant5
Interactions between amyloid fibril proteins5
Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays4
High frequency of occult transthyretin and apolipoprotein AI–type amyloid in aortic valves removed by valve replacement for aortic stenosis4
Computed tomography-derived myocardial radiomics for detection of transthyretin amyloidosis in patients with severe aortic stenosis4
Hereditary transthyretin amyloidosis with cardiomyopathy and polyneuropathy associated with a novel pathogenic TTR Tyr105His (p.Tyr125His) mutation4
Usefulness of the Columbia score for predicting outcomes in patients with transthyretin amyloid cardiomyopathy. Analysis of the Galician registry of cardiac amyloidosis4
A cautionary case series: tafamidis mistreatment following erroneous diagnosis of transthyretin cardiac amyloidosis4
High rate of false negative 99m Tc-pyrophosphate scintigraphy scans in patients with Leu58His transthyretin amyloid cardiomyopathy4
A comparison of single versus combination mechanism treatment for transthyretin amyloid cardiomyopathy4
The way to a man’s heart: prostate samples for the early detection of transthyretin cardiomyopathy4
PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study4
A collaborative approach to amyloidosis and a multidisciplinary care framework – position statement from the International Society of Amyloidosis4
Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy4
Diagnostic and prognostic contribution of DPD scintigraphy in transthyretin V30M cardiac amyloidosis4
Technetium-99m-pyrophosphate imaging-based computed tomography-guided core-needle biopsy of internal oblique muscle in wild-type transthyretin cardiac amyloidosis4
A novel substitution of proline (P32L) destabilises β2-microglobulin inducing hereditary systemic amyloidosis4
Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee4
Longitudinal PET/CT imaging with iodine ( 124 I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis4
Global patterns of amyloid typing: results of a survey by the International Society of Amyloidosis (ISA)4
The impact of Post-Transplant doxycycline in AL amyloidosis – updated results after Long-Term follow up4
Functional and morphometric assessment of small-fibre damage in late-onset hereditary transthyretin amyloidosis with polyneuropathy: the controversial relation between small-fibre-related symptoms and3
Quantitative sensory testing: a good tool to identify subclinical neuropathy in ATTRV30M amyloidosis patients?3
Transthyretin monomers: a new plasma biomarker for pre-symptomatic transthyretin-related amyloidosis3
Internalisation of immunoglobulin light chains by cardiomyocytes in AL amyloidosis: what can biopsies tell us?3
Identification of calcitonin receptor-stimulating peptide 1-derived amyloid in a feline C-cell carcinoma3
AA amyloidosis in vertebrates: epidemiology, pathology and molecular aspects3
Regarding the challenges of amyloidosis diagnosis and typing in Ukraine3
Binding of serum-derived amyloid-associated proteins to amyloid fibrils3
Mass spectrometry-based proteomic analysis of proteins adsorbed by hexadecyl-immobilized cellulose bead column for the treatment of dialysis-related amyloidosis3
ATTR- and AFib amyloid - two different types of amyloid in the annular ligament of trigger finger3
Suboptimal response for AL amyloidosis: is it time for early switch? Experience from a single amyloid program3
Optimized methods for efficient application of immunogold electron microscopy to amyloid fibrils typing3
Hereditary gelsolin amyloidosis: a rare cause of cranial, peripheral and autonomic neuropathies linked to D187N and Y447H substitutions2
XIX International Symposium on Amyloidosis Abstracts2
Hereditary transthyretin amyloidosis in middle-aged and elderly patients with idiopathic polyneuropathy: a nationwide prospective study2
Distribution and progression of cerebral amyloid angiopathy in early-onset V30M (p.V50M) hereditary ATTR amyloidosis2
In memoriam: Lawreen Connors, Ph.D.2
Neurofilament light chain kinetics as a biomarker for polyneuropathy in V122I hereditary transthyretin amyloidosis2
The integration of genetically-regulated transcriptomics and electronic health records highlights a pattern of medical outcomes related to increased hepatic transthyretin 2
Collagen inhibits phagocytosis of amyloid in vitro and in vivo and may act as a ‘don’t eat me’ signal2
A report from the European Proteomics Amyloid Network (EPAN)2
The flutemetamol analogue cyano-flutemetamol detects myocardial AL and ATTR amyloid deposits: a post-mortem histofluorescence analysis2
CSF/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis2
Iatrogenic cerebral amyloid angiopathy rather than sporadic CAA in younger adults with lobar intracerebral haemorrhage2
T2-relaxometry in a large cohort of hereditary transthyretin amyloidosis with polyneuropathy2
Prevalence of amyloid in ligamentum flavum of patients with lumbar spinal stenosis2
Genetic counselling for at-risk family members with hereditary transthyretin amyloidosis: data from a single-centre study2
No body fits in the test tube – the case of transthyretin2
Correlation of 99mTc-DPD bone scintigraphy with histological amyloid load in patients with ATTR cardiac amyloidosis2
Prevalence and diagnostic value of extra-left ventricle echocardiographic findings in transthyretin-related cardiac amyloidosis2
Right ventricular-pulmonary arterial coupling and outcomes in cardiac amyloidosis: systematic review and meta-analysis2
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis2
Amyloidosis from the patient perspective: the French daily impact of amyloidosis study2
0.29794597625732